VSW1198

a potent GGDPS inhibitor; structure in source; a 3:1 mixture of homogeranyl and homoneryl isomers

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

1.	Neoplasms (Cancer) 05/10/2018 - "The validated method was used for quantitative determination of the compounds in preclinical studies focused on the development of VSW1198 as a novel anti-cancer agent."
2.	Multiple Myeloma 05/10/2018 - "An isomeric mixture of homogeranyl/homoneryl triazole bisphosphonates (VSW1198) has previously been shown to be a potent inhibitor of geranylgeranyl diphosphate (GGDP) synthase (GGDPS) and of therapeutic interest for the treatment of multiple myeloma. "

1.	Farnesyltranstransferase (Farnesyltransferase)
2.	Triazoles
3.	Diphosphonates (Bisphosphonates)
4.	geranylgeranyl pyrophosphate (geranylgeranyl diphosphate)